Cardiology and Cardiovascular Research

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Research Article |

Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville

Pulmonary Arterial Hypertension PAH is a medical condition serious and severe. In Congo, its epidemiology and its etiologies are poorly understood. This study, aimed at improving the care of patients with PAH, was interested to epidemio-clinical aspects, and prognosis of this entity. This was a retrospective, cross-sectional study carried out from the 1st January 2021 to December 31, 2022 (2 years) in Brazzaville University Hospital. Were included 148 patients, the diagnostic criteria having permit to retain a PAH were compliant to that of the PAPUCO study (PAH if PAPS ≥ 35 mmHg, severe PAH if PAPS ≥ 60 mmHg). The heart failure syndrome was present in 140 cases (94.6%), it was right exclusively in 36 cases (24.3%). The etiologies of the group, they were present in 97 cases (66%) followed group III in 24 cases (16.2%). PAH was said to be severe in 39 cases (26.3%). The evolution has been towards complications in 29 cases (19.6%), lethality in 17 cases (11.5%). Poor prognosis factors were the existence of underlying heart disease underlying (AOR =5.6; p =0.02), male sex (AOR=4.8; p=0.02); hyperkalemia (AOR= 9.4; p=0.00). High blood pressure pulmonary is an increasingly common condition encountered in clinical practice in our context.

PAH, Left Heart Disease, Brazzaville, Congo

APA Style

Ngamami, S. F. M., Taty, R. J., Letomo, K. M. N., Landa, C. M. K., Naibe, G. T., et al. (2024). Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiology and Cardiovascular Research, 8(1), 1-6. https://doi.org/10.11648/j.ccr.20240801.11

ACS Style

Ngamami, S. F. M.; Taty, R. J.; Letomo, K. M. N.; Landa, C. M. K.; Naibe, G. T., et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol. Cardiovasc. Res. 2024, 8(1), 1-6. doi: 10.11648/j.ccr.20240801.11

AMA Style

Ngamami SFM, Taty RJ, Letomo KMN, Landa CMK, Naibe GT, et al. Pulmonary Arterial Hypertension: Epidemiological, Clinical Aspects and Prognoses in the Cardiology Department and Internal Medicine of CHU Brazzaville. Cardiol Cardiovasc Res. 2024;8(1):1-6. doi: 10.11648/j.ccr.20240801.11

Copyright © 2024 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 11 oct 2022; 43(38): 3618 731.
2. Collège national des enseignants de cardiologie et de la société française. Cardiologie. 2E édition ELSEVIER MASSON, Paris 2015; 284 P.
3. Thienemann F, Dzudie A, Mocumbi AO, et al. Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. BMJ Open. 2014; 4(10): e005950.
4. Galiè N, Humbert M, Vachiery JL, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1): 67-119, 2016.
5. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022; 2200879.
6. Jingi AM, Noubiap JJ et al. Prevalence and determinants of pulmonary hypertension in a group of Cameroonian patients without chronic lung disease: a cross-sectional echocardiographic study. BMC Res Notes 2017; 10: 571.
7. Koné A, Koffi MOB, Samaké K, Djegbeton A, Kouraogo BW, Mobio LNA, et al. Difficulties in the management of pulmonary hypertension in a pneumology department in Abidjan, Côte d'Ivoire. Revue des Maladies Respiratoires Actualités. 2023; 15(1): 211 2.
8. Balola MB, Mateso GQM, Munyerenkana RB, Nzabara F, Maheshe G. Causes of pulmonary hypertension in South Kivu, case of Bukavu Provincial General Reference Hospital. Ann afr méd (Online). 2020; 3829 39.
9. Ovaga BE. Exclusive right heart failure in the Department of Cardiology and Internal Medicine at Brazzaville University Hospital. Thèse de Médecine. Université Marien Ngouabi; 2016, 74P. v.
10. Simonneau G, Moutari D et al. Haemodynamic definitions and updated Clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.
11. Rochon ER, Krowka MJ, Bartolome S, et al: BMP 9/10 in pulmonary vascular complications of liver disease. Am J Respir Crit Care Med 201(11): 1575–1578, 2020. doi: 10.1164/rccm.201912-2514LE.
12. Beghetti M, Simonneau G. Classification de l’hypertension artérielle pulmonaire. Arch Cardiol Desease 2010; 2: 132-136.
13. Reinero C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, et al. ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med. mars 2020; 34(2): 549 73.
14. Choudhary G, Jankowich M. Prevalence and Clinical Characteristics Associated with Pulmonary Hypertension in African-Americans. PloS One. 2013. 8(12): e84264.
15. Enea I, Ghio S et al. Echocardiographic alterations suggestive of pulmonary hypertension in the italian ultrasonography laboratories. Epidemiological data from the INCIPT study. G Ital Cardiol. Rome. 2010. 11: 402-407.
16. Sobanski V, Sanges S, Launay D, Humbert M. Hypertension pulmonaire et connectivites. Revue du rhumatisme monographies. 2018; 85(3): 210 20.
17. Badesch DB, Raskob GE. Pulmonary arterial hypertension: Baseline charactéristics from the REVEAL registry. Chest 2010: 137(2): 376-387.
18. Dzudie A et al. Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. Cardiovasc J Afr 2018; 29(4): 208-212.
19. Ngunga M et al. Long-Term Outcomes and Factors Associated with Mortality in Patients with Moderate to Severe Pulmonary Hypertension in Kenya. Global Heart. 2020; 15(1); 6.
20. Vachiéry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. janv 2019; 53(1): 1801897.
21. Ikama SM et al. Epidemiological and clinical profile of dilated cardiomyopathy at the Centre Hospitalier Universitaire de Brazzaville, Congo. Pan African Medical Journal. 2018; 31: 164.
22. Cassady SJ, Ramani GV. Right Heart Failure in Pulmonary Hypertension. Cardiol Clin. mai 2020; 38(2): 243 55.
23. Cappola et al. Pulmonary hypertension and myocarditis: a higher risk of death. Circulation 2002. (https://www.caducee.net/actualité-medicale/3554/hypertension-pulmonaire-et-myocardite.html).
24. Maloir Q, PETITJEAN H, Parzibut G, Weber T, DAVIDSEN C, Dulgheru E, et al. New developments in the diagnosis and risk stratification of pulmonary hypertension. Revue Médicale de Liège [Internet]. 2023 [cited 19 Nov 2023]; 78(2). Available from: https://orbi.uliege.be/handle/2268/300917